Antigen News and Research

RSS

VSV-based vaccine yields promising results for rapid development of effective Ebola vaccine

A live vaccine based on the "Vesicular Stomatitis Virus" (VSV) has yielded highly promising results for the rapid development of an effective vaccine against the Ebola virus. This vaccine would only need to be injected once for long-lasting immunoprotection.

2 Apr 2015

Antibodies from dromedary camels may prove therapeutic for MERS patients

Antibodies from dromedary camels protected uninfected mice from Middle East Respiratory Syndrome (MERS), and helped infected mice expunge the disease, according to a study published online March 18th in the Journal of Virology, a journal published by the American Society for Microbiology.

31 Mar 2015

Merck Serono, Intrexon partner to develop and commercialize CAR-T cancer therapies

Merck Serono, the biopharmaceutical business of Merck, and Intrexon Corporation, today announced an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies.

30 Mar 2015

Fujifilm enters into definitive agreement to acquire Cellular Dynamics International

FUJIFILM Holdings Corporation (President: Shigehiro Nakajima) and Cellular Dynamics International, Inc. (CEO: Robert J. Palay), a leading developer and manufacturer of fully functioning human cells in industrial quantities to precise specifications, today announced that the two companies have entered into a definitive agreement whereby Fujifilm will acquire CDI via an all-cash tender offer to be followed by a second step merger.

30 Mar 2015

DFG Senate approves establishment of one Clinical Research Unit, five Research Units

At its spring meeting in Bonn, the Senate of the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) approved the establishment of one new Clinical Research Unit and five new Research Units.

30 Mar 2015

Wyatt Technology’s CG-MALS system enables characterization of complex protein-protein interactions

Study published in Nature outlines use of Wyatt’s Calypso II system to confirm the stoichiometry of αSNAP-SNARE complex

From Waters | Wyatt Technology 26 Mar 2015

Study: HBV exposure increases immune system maturation of infants

A Singapore led study has shown that Hepatitis B Virus Infection (HBV) exposure increases the immune system maturation of infants, which may give a better survival advantage to counteract bacterial infection during early life. These findings radically modify the way that HBV vertical infection of neonates (mother-to-child) is portrayed, and present a paradigm shift in the approach to treatment of patients with chronic hepatitis B.

26 Mar 2015

Theravectys gets authorization to produce lentiviral vectors for clinical use and CAR-T cell-based immunotherapy

THERAVECTYS, a clinical development biotechnology company that focuses on the development of therapeutic vaccines and immunotherapies, proudly announces that its manufacturing plant has obtained the status of a pharmaceutical manufacturing establishment, granted by the French National Agency for Medicines and Health Products Safety.

26 Mar 2015

Personalized gene therapy to fight against cancer

The fight to treat cancer and eradicate tumors will likely benefit from a new set of treatments if early development phases continue to show promise, according to Kalorama Information. The healthcare market research publisher stated that gene therapies that are able to deliver genetic material to a specific cell population or tumor that will result in the destruction of the tumor.

25 Mar 2015

New approach to treating B-ALL tumour disease

B cell acute lymphoblastic leukaemia, or B-ALL, is the most common tumour disease in children and also occurs in adults. It develops when signalling pathways in immature B cells, or pre-B cells, are dysregulated. Prof. Dr. Markus Müschen from the University of California in San Francisco, USA, and his team worked together with the BIOSS researchers Prof. Dr. Hassan Jumaa and Prof. Dr. Michael Reth to find a new approach for treating the B-ALL tumour disease.

25 Mar 2015

TxCell to present at upcoming US and French investment conferences

Damian Marron, CEO, TxCell, will present at the Alliance for Regenerative Medicine's 3rd Annual Regen Med Investor Day, New York, March 25, 2015. In addition, Damian Marron will also participate at the Portzamparc PEA-PME Forum, Paris, April 1, 2015.

24 Mar 2015

Newly discovered bodily process may explain fetal brain bleeds

A newly discovered bodily process in mice may explain why some human fetuses who have different antigens than their mothers suffer life-threatening brain bleeds, according to a new study.

24 Mar 2015

Radiation treatment can be delayed after prostatectomy to prevent side effects, say studies

Important news for men receiving treatment for prostate cancer: Two new studies from the University of Virginia School of Medicine have upended the widely held view that it's best to delay radiation treatment as long as possible after the removal of the prostate in order to prevent unwanted side effects.

23 Mar 2015

New triple combination therapy shows promise in controlling advanced melanoma

Results of a new study by UCLA researchers has found that a groundbreaking new triple combination therapy shows promising signs of more effectively controlling advanced melanoma than previous BRAF + MEK inhibitor or BRAF inhibitor + immunotherapy combos alone, and with increased immune response and fewer side effects.

20 Mar 2015

Researchers find way to enhance effects of immunotherapy in glioblastoma

When cancer strikes, it may be possible for patients to fight back with their own defenses, using a strategy known as immunotherapy. According to a new study published in Nature, researchers have found a way to enhance the effects of this therapeutic approach in glioblastoma, a deadly type of brain cancer, and possibly improve patient outcomes.

20 Mar 2015

Researchers successfully generate cells of immune system to target, destroy cancer cells

Researchers at the Max Delbrück Center for Molecular Medicine Berlin-Buch and Charité - Universitätsmedizin Berlin, Campus Berlin-Buch, have succeeded in generating cells of the immune system to specifically target and destroy cancer cells.

20 Mar 2015

ImmunoCellular, PharmaCell sign manufacturing agreement for European production of ICT-107

ImmunoCellular Therapeutics, Ltd. today announced the establishment of an agreement with PharmaCell B.V. to provide contract manufacturing services for the European production of ICT-107, a dendritic cell-based cancer immunotherapy in development as a potential treatment for glioblastoma (GBM).

19 Mar 2015

TxCell to receive US patent for Ovasave to treat inflammatory bowel disease

TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces that a key patent is to be granted on March 31 2015 by the United States Patent and Trademark Office.

19 Mar 2015

Physicians, researchers to discuss advances in cancer immunotherapies at UChicago symposium

The Ben May Department for Cancer Research at the University of Chicago will hold a day-long symposium on cancer immunotherapy for physicians and researchers.

18 Mar 2015

Study may help men make better decisions about aggressive prostate cancer treatments

A Northwestern University-led study in the emerging field of nanocytology could one day help men make better decisions about whether or not to undergo aggressive prostate cancer treatments.

17 Mar 2015

Antigen News and Research

VSV-based vaccine yields promising results for rapid development of effective Ebola vaccine

Antibodies from dromedary camels may prove therapeutic for MERS patients

Merck Serono, Intrexon partner to develop and commercialize CAR-T cancer therapies

Fujifilm enters into definitive agreement to acquire Cellular Dynamics International

DFG Senate approves establishment of one Clinical Research Unit, five Research Units

Wyatt Technology’s CG-MALS system enables characterization of complex protein-protein interactions

Study: HBV exposure increases immune system maturation of infants

Theravectys gets authorization to produce lentiviral vectors for clinical use and CAR-T cell-based immunotherapy

Personalized gene therapy to fight against cancer

New approach to treating B-ALL tumour disease

TxCell to present at upcoming US and French investment conferences

Newly discovered bodily process may explain fetal brain bleeds

Radiation treatment can be delayed after prostatectomy to prevent side effects, say studies

New triple combination therapy shows promise in controlling advanced melanoma

Researchers find way to enhance effects of immunotherapy in glioblastoma

Researchers successfully generate cells of immune system to target, destroy cancer cells

ImmunoCellular, PharmaCell sign manufacturing agreement for European production of ICT-107

TxCell to receive US patent for Ovasave to treat inflammatory bowel disease

Physicians, researchers to discuss advances in cancer immunotherapies at UChicago symposium

Study may help men make better decisions about aggressive prostate cancer treatments

Industry Focus eBook - Cell biology (5th edition) eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics